Rubius Therapeutics

76 articles with Rubius Therapeutics

• 

  Biotech Manufacturing is Booming with Growth of Biologics and Gene Therapies

  7/5/2018

  Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
• 

  Rubius Therapeutics Looks to Raise $200 Million in IPO for Red-Cell Therapies

  6/27/2018

  Three months after securing $100 million in a crossover financing round, Cambridge, Mass.-based Rubius Therapeutics is looking at a $200 million initial public offering to support its personalized red blood cell therapeutics program.
• 

  BioSpace Movers and Shakers for Week of June 4th

  6/11/2018

  Biotech and pharmaceutical companies across the U.S. and globally shook up their senior leadership roles in the first week of June with new hires that included chief executive officers and directors.

• Rubius Therapeutics Appoints Pablo J. Cagnoni, M.D. as Chief Executive Officer

  6/6/2018

  Torben Straight Nissen, Rubius’ President, will partner with Dr. Cagnoni to continue to advance the company’s pipeline and other business objectives.

• 

  Biotech Companies Continue to Shake Up Leadership with New Appointments

  5/8/2018

  There have been a number of leadership changes in biotech companies over the last week. BioSpace has put together a list of new c-suite level hires and position changes.
• 

  More Women Named to Life Science Boards of Directors but Gender Gap Continues

  5/3/2018

  Despite raised awareness over the past few years, the gender diversity gap in the boardrooms of Fortune 1000 companies has remained at slightly less than 20 percent, as of 2017. There is evidence though that shows companies with more diversity at the highest levels see a higher return on investme...

• Rubius Therapeutics Appoints Jonathan R. Symonds to Board of Directors

  5/2/2018

  Rubius Therapeutics, a biotechnology company pioneering the development of a versatile new class of ready-to-use cellular therapies, today announced the appointment of Jonathan R. Symonds, CBE, to its board of directors.

• 

  VCs Are Pouring Billions into Biotech in 2018

  3/6/2018

  While the focus has been on M&A activity, Venture Capital firms have been investing billions in Biotech companies in 2018.
• 

  Rubius Therapeutics Raises $100 Million in Crossover Financing

  3/1/2018

  Rubius Therapeutics has closed on an oversubscribed $100 million crossover financing.
• 

  Biotech Startup Rubius to Double Footprint With New Kendall Square Lease

  2/12/2018

  The fast-growing company will anchor 399 Binney St., an Alexandria Real Estate Equities property.

• Rubius Therapeutics Appoints Francis Cuss and Catherine Sohn to Board of Directors

  2/1/2018

  Rubius Therapeutics today announced the appointments of Francis Cuss, MB, MChir, FRCP and Catherine Sohn, Pharm.D., to its board of directors.

• Rubius Therapeutics Strengthens Leadership Team With Appointment of Andrew Oh as Chief Financial Officer

  12/14/2017

  Mr. Oh brings to Rubius more than 20 years of experience in finance and the biopharmaceutical industry.

• Rubius Poaches New CMO From GlaxoSmithKline

  9/27/2017

• Cell Therapy Pioneer David Epstein Expands Role With Rubius To Become Executive Chairman

  8/8/2017

• Cambridge Biotech Startup Rubius Banks $120 Million, Hopes to Hire 60 New Staffers

  6/22/2017

• Rubius Therapeutics Announces Appointment Of Top Leadership

  1/4/2017